JP2003516353A5 - - Google Patents

Download PDF

Info

Publication number
JP2003516353A5
JP2003516353A5 JP2001543106A JP2001543106A JP2003516353A5 JP 2003516353 A5 JP2003516353 A5 JP 2003516353A5 JP 2001543106 A JP2001543106 A JP 2001543106A JP 2001543106 A JP2001543106 A JP 2001543106A JP 2003516353 A5 JP2003516353 A5 JP 2003516353A5
Authority
JP
Japan
Prior art keywords
valdecoxib
composition
compositions
acid
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001543106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003516353A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/032417 external-priority patent/WO2001041761A2/en
Publication of JP2003516353A publication Critical patent/JP2003516353A/ja
Publication of JP2003516353A5 publication Critical patent/JP2003516353A5/ja
Pending legal-status Critical Current

Links

Images

JP2001543106A 1999-12-08 2000-12-04 ヴァルデコキシブ組成物 Pending JP2003516353A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16985699P 1999-12-08 1999-12-08
US60/169,856 1999-12-08
US18163500P 2000-02-10 2000-02-10
US60/181,635 2000-02-10
US20226900P 2000-05-05 2000-05-05
US60/202,269 2000-05-05
PCT/US2000/032417 WO2001041761A2 (en) 1999-12-08 2000-12-04 Valdecoxib compositions

Publications (2)

Publication Number Publication Date
JP2003516353A JP2003516353A (ja) 2003-05-13
JP2003516353A5 true JP2003516353A5 (cg-RX-API-DMAC7.html) 2005-11-17

Family

ID=27389729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001543106A Pending JP2003516353A (ja) 1999-12-08 2000-12-04 ヴァルデコキシブ組成物

Country Status (29)

Country Link
US (1) US20020013357A1 (cg-RX-API-DMAC7.html)
EP (1) EP1165072A2 (cg-RX-API-DMAC7.html)
JP (1) JP2003516353A (cg-RX-API-DMAC7.html)
KR (2) KR100664479B1 (cg-RX-API-DMAC7.html)
CN (2) CN1203852C (cg-RX-API-DMAC7.html)
AR (1) AR027896A1 (cg-RX-API-DMAC7.html)
AU (3) AU1930301A (cg-RX-API-DMAC7.html)
BG (1) BG105873A (cg-RX-API-DMAC7.html)
BR (1) BR0008059A (cg-RX-API-DMAC7.html)
CA (1) CA2362816C (cg-RX-API-DMAC7.html)
CO (1) CO5261582A1 (cg-RX-API-DMAC7.html)
CR (1) CR6458A (cg-RX-API-DMAC7.html)
CZ (1) CZ20013163A3 (cg-RX-API-DMAC7.html)
EA (1) EA003639B1 (cg-RX-API-DMAC7.html)
EE (1) EE200100414A (cg-RX-API-DMAC7.html)
HK (1) HK1041637A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20010582A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0200409A3 (cg-RX-API-DMAC7.html)
IL (2) IL144763A0 (cg-RX-API-DMAC7.html)
IS (1) IS6040A (cg-RX-API-DMAC7.html)
MY (1) MY138227A (cg-RX-API-DMAC7.html)
NO (1) NO20013858L (cg-RX-API-DMAC7.html)
NZ (1) NZ513963A (cg-RX-API-DMAC7.html)
PE (1) PE20010940A1 (cg-RX-API-DMAC7.html)
PL (1) PL351069A1 (cg-RX-API-DMAC7.html)
SK (1) SK12692001A3 (cg-RX-API-DMAC7.html)
TR (1) TR200102297T1 (cg-RX-API-DMAC7.html)
TW (1) TWI265808B (cg-RX-API-DMAC7.html)
WO (2) WO2001041761A2 (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1162890B1 (en) 1998-10-30 2005-10-12 RJ Innovation A method of preventing parturient hypocalcemia in animals and compositions used therein
YU43702A (sh) 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
AU2002303577B2 (en) * 2001-05-04 2006-06-08 Merck & Co., Inc. Method and compositions for treating migraines
EP1429736A2 (en) * 2001-09-26 2004-06-23 Pharmacia Corporation Organoleptically acceptable intraorally disintegrating compositions
CN1602187A (zh) * 2001-10-10 2005-03-30 法马西亚公司 通过喷雾干燥法制备的口内崩解的伐地考昔组合物
GB0124459D0 (en) * 2001-10-11 2001-12-05 Novartis Ag Organic compounds
CA2466030A1 (en) * 2001-11-07 2003-05-15 Pharmacia Corporation Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
MXPA04004476A (es) * 2001-11-13 2004-08-11 Pharmacia Corp Forma de dosificacion oral de un profarmaco la sulfonamida.
AU2003207453A1 (en) * 2002-01-07 2003-07-24 Pharmacia Corp Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
RU2286151C2 (ru) * 2002-02-22 2006-10-27 Уорнер-Ламберт Компани Ллс Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
IL163846A0 (en) * 2002-03-01 2005-12-18 Univ South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
GB0209257D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
EP1524997A1 (en) * 2002-06-26 2005-04-27 Pharmacia Corporation Stable liquid parenteral parecoxib formulation
MXPA05001707A (es) * 2002-08-30 2005-04-19 Pharmacia Corp Formas de dosificacion farmaceutica solidas que presentan un perfil de liberacion de farmaco reproducible,.
US20060052432A1 (en) * 2002-09-20 2006-03-09 Julius Remenar Pharmaceutical compositions with improved dissolution
JP4494712B2 (ja) * 2002-11-12 2010-06-30 大日本住友製薬株式会社 マルチプルユニット型徐放性製剤
DE50312678D1 (de) 2002-11-22 2010-06-10 Gruenenthal Gmbh Verwendung von (1R, 2R)-3-(3-Dimenthylamino-1-ethyl-2-methyl-propyl)-phenol zur Behandlung von Entzündungsschmerz
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
US20050004224A1 (en) * 2003-06-10 2005-01-06 Pharmacia Corporation Treatment of Alzheimer's disease with the R(-) isomer of a 2-arylpropionic acid non-steroidal anti-inflammatory drug alone or in combination with a cyclooxygenase-2 selective inhibitor
US20050080083A1 (en) * 2003-07-10 2005-04-14 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage
BRPI0415753A (pt) * 2003-10-21 2006-12-19 Pharmacia Corp método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
JP4997109B2 (ja) 2004-09-01 2012-08-08 ユーロ−セルティーク エス.エイ. 用量比例的な定常状態caveおよび定常状態auc、ならびに、用量比例よりも小さい単回投与cmaxを有するオピオイド投薬形態物
RU2007139819A (ru) * 2005-03-29 2009-05-10 МакНЕЙЛ-Пи-Пи-Си, ИНК. (US) Композиции с гидрофильными лекарствами в гидрофобной среде
HRP20151051T1 (hr) * 2005-05-05 2015-11-06 Bristol-Myers Squibb Holdings Ireland Formulacije src/abl inhibitora
US7942818B2 (en) * 2006-02-01 2011-05-17 University Of Florida Research Foundation, Inc. Obstetric analgesia system
WO2007109244A2 (en) 2006-03-21 2007-09-27 Morehouse School Of Medicine Novel nanoparticles for delivery of active agents
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
EP2124901B1 (en) * 2007-02-01 2017-07-19 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
FR2963889B1 (fr) * 2010-08-20 2013-04-12 Debregeas Et Associes Pharma Formulations a base de nalbuphine et leurs utilisations
BR112020002967A2 (pt) 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
TWI803504B (zh) * 2017-08-14 2023-06-01 美商雲杉生物科技股份有限公司 促皮質素釋放因子受體拮抗劑
MX2020011344A (es) 2018-04-27 2021-02-09 Spruce Biosciences Inc Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
CN108644512B (zh) * 2018-07-09 2023-06-30 南京氟源化工管道设备有限公司 一种钢衬聚四氟乙烯三通及其模压工艺
CN116473973A (zh) * 2018-12-24 2023-07-25 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物的治疗用途及其固体药物组合物
JP2023537598A (ja) 2020-08-12 2023-09-04 スプルース バイオサイエンシーズ,インク. 多嚢胞性卵巣症候群を処置するための方法および組成物
US11273128B1 (en) * 2021-04-15 2022-03-15 Sandoz Ag Elagolix formulation
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3267300B2 (ja) * 1995-02-13 2002-03-18 ジー.ディー.サール アンド カンパニー 炎症の治療のための置換イソオキサゾール
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CA2363590A1 (en) * 1999-03-10 2000-09-14 G.D. Searle & Co. Method and composition for administering a cyclooxygenase-2 inhibitor

Similar Documents

Publication Publication Date Title
AU777402B2 (en) Valdecoxib compositions
EP1150959B1 (en) Solid-state form of celecoxib having enhanced bioavailability
ES2236007T3 (es) Composiciones de inhibidor de ciclooxigenasa-2 ue tiene un efecto terapeutico rapido.
AU2001286530B2 (en) Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
US20020119193A1 (en) Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
AU2001286530A1 (en) Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
WO2003026623A1 (en) Intraorally disintegrating valdecoxib compositions
WO2001041536A2 (en) Solid-state form of celecoxib having enhanced bioavailability
JP2006321820A (ja) 安定な無定形セレコキシブ複合物およびその製法
MXPA01008055A (en) Valdecoxib compositions
AU2002341796A1 (en) Intraorally disintegrating valdecoxib compositions